Circulars

Back to Circulars

16 November 2017

Ministry Of Health And Prevention Safety Alerts And Warnings For The Month Of October 2017

Reference: CIR-2017-SHN0781

In accordance with the recommendations of the Ministry of Health and Prevention and interest to maintain community and publichealth safety, we would like to draw your attention to the  following safety alerts and warnings for October 2017.

In accordance with the recommendations of the Ministry of Health and Prevention and interest to maintain community and public health safety, we would like to draw your attention to the following safety alerts and warnings for October 2017 :
1.      Medication Safety alert of using one batch of Paracetamol10mg/ml Intravenous infusion of the company Pharmaceutical Solutions Industries.  
2.       Medication Safety Alert and Warning of using compound drugs Triamcinolone, Moxifloxacin, and Vancomycin Formulation that lead to clogged arteries and inflammation of blood vessels in the eye.
3.       Medication Safety Alert and Warning of dispensing BLINCYTO (blinatumomab) manufactured by AMGEN Company.
4.       Medication Safety alert and Warning against the use of skin whitening kits and glutathione products through intravenous or subcutaneous injection.
5.       Medical Device Safety Alert Withdrawal of several batches of Reverse Shoulder System from the manufacture company Depuy Synthes Delta XTEND. 
6.      Medical Device Safety Alert of All Carestation 620/650/650c anesthesia systems from the American company (GE Healthcare.).
7.      Medical Device Safety Alert of Alaris GS, GH, CC, TIVA, PK, Enteral Syringe Pumps, and, Asena GS, GH, CC, TIVA, PK, Syringe Pumps manufactured by CareFusion.
8.      Medical Device Safety Alert of BD MAX  manufactured by Becton Dickinson.
9.      Medical Device Safety Alert of All Metal-on-Metal (MoM) Hip replacements.
For more information on the above safety alert, and to keep up to date with safety alerts  please visit MOHP website:

http://www.cpd-pharma.ae

§  To report Adverse Drug Reaction(ADR) or Event, kindly fill out the ADR form available at the website:

http://www.cpd-pharma.ae
Or contact the following addresses: Tel: 04-2301448 or fax 04-2301947 or Email address: pv@moh.gov.ae

§  All healthcare facilities should work in accordance with the instructions as mentioned above to avoid any violations or penalties in this regard. In addition, should not use the mentioned Lot/Batch Number if available.

§  For more information, kindly contact the support office @ Health Regulation Dept. on :

Telephone: 04-5022901 / 5022996

 

Email address: regulation@dha.gov.ae

For full access on circular # 124, please refer to the following link:

 

https://www.dha.gov.ae/Documents/%D8%AA%D8%B9%D9%85%D9%8A%D9%85%20%D8%B1%D9%82%D9%85%20124%20%D8%A8%D8%B4%D8%A3%D9%86%20%D8%AA%D8%AD%D8%B0%D9%8A%D8%B1%D8%A7%D8%AA%20%D9%88%D8%AA%D9%86%D8%A8%D9%8A%D9%87%D8%A7%D8%AA%20%D8%A7%D9%84%D8%B3%D9%84%D8%A7%D9%85%D8%A9%20%D9%85%D9%86%20%D9%88%D8%B2%D8%A7%D8%B1%D8%A9%20%D8%A7%D9%84%D8%B5%D8%AD%D8%A9%20%D9%88%D9%88%D9%82%D8%A7%D9%8A%D8%A9%20%D8%A7%D9%84%D9%85%D8%AC%D8%AA%D9%85%D8%B9%20%D9%84%D8%B4%D9%87%D8%B1%20%D8%A3%D9%83%D8%AA%D9%88%D8%A8%D8%B1%202017.pdf

Your co-operation is highly appreciated,                              

with regards , Health Regulation Department /DHA

            

     

Close